12% of Pharma Jobs Are Re-Posts - Weekly Roundup July 7, 2025
Job posting dropped sharply last week across the US pharma industry, likely due to the 4th of July holiday. Among the 59 companies we track, only Novartis defied this trend, posting 55% more roles than their 8-week average.
Hiring Leaders: Medtronic (288 new postings), followed by Takeda (281 new postings) and Johnson and Johnson (193 new postings).
When Pharma Re-Posts Roles ¶
PharmaPayWatch tracks more than just current openings. We monitor when jobs are posted, removed, and re-posted using internal company job IDs and title/description comparison.
This data can reveal which roles are hard to fill and where candidates might have stronger negotiating power.
Our Q1 2025 analysis of 16,270 US job postings found that nearly 12% (1,882) were re-posts - positions that companies removed and then re-posted after an average gap of 13 days.
Key findings:
- Moderna had the highest re-post rate with 51% of roles being re-posts (64 out of 126 total)
- Most salaries remained the same between re-posts, but a subset (7%) changed between re-posts, indicating a re-adjustment to market conditions
- Jobs that were re-posted only once were most likely to adjust salary, the more reposts the less likely for a salary adjustment
- Commercial, Software & IT, and Scientific Research roles were re-posted most frequently
What’s Next ¶
Next week, I’ll dig deeper into specific jobs, salary changes, and investigate the suspiciously high repost rate for Moderna.
Questions about this data or want to see analysis of a specific company or feature? Reply to this email!
Data from PharmaPayWatch.com | US jobs only | Questions? Reply to this email or reach out to [email protected]